Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer

被引:0
|
作者
Sznarkowska, Alicja [1 ]
Olszewski, Robert [1 ]
Zawacka-Pankau, Joanna [1 ]
机构
[1] Uniwersytetu Gdanskiego Gdanskiego Uniwersytetu M, Miedzyuczelniany Wydzial Biotechnol, Pracownia Diagnost Mol, Katedra Biotechnol, PL-80822 Gdansk, Poland
关键词
p53 tumor suppressor protein; MDM2; p53-HDM2; complex; proteasomal degradation; apoptosis; antitumor therapy; low molecular weight compounds; IN-VIVO; P53-DEPENDENT APOPTOSIS; PHOTODYNAMIC THERAPY; ANTICANCER THERAPY; MDM2; INHIBITORS; DNA-DAMAGE; CELL-DEATH; PROTEIN; PATHWAY; INTERACTS;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A powerful tumor suppressor - p53 protein is a transcription factor which plays a critical role in eliciting cellular responses to a variety of stress signals, including DNA damage, hypoxia and aberrant proliferative signals, such as oncogene activation. Since its discovery thirty one years ago, p53 has been connected to tumorigenesis as it accumulates in the transformed tumor cells. Cellular stress induces stabilization of p53 and promotes, depending on the stress level, cell cycle arrest or apoptosis in the irreversibly damaged cells. The p53 protein is found inactive in more than 50% of human tumors either by enhanced proteasomal degradation or due to the inactivating point mutations in its gene. Numerous data indicate that low molecular weight compounds, identified by molecular modeling or in the functional, cell-based assays, efficiently activate non-mutated p53 in cancer cells which in consequence leads to their elimination due to p53-dependent apoptosis. In this work we describe the structure and cellular function of p53 as well as the latest discoveries on the compounds with high anti-tumor activities aiming at reactivation of the tumor suppressor function of p53.
引用
收藏
页码:396 / 407
页数:12
相关论文
共 50 条
  • [31] Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand
    Naumann, U
    Kügler, S
    Wolburg, H
    Wick, W
    Rascher, G
    Schulz, JB
    Conseiller, E
    Bähr, M
    Weller, M
    CANCER RESEARCH, 2001, 61 (15) : 5833 - 5842
  • [32] MUTATIONS OF THE P52 TUMOR-SUPPRESSOR GENE IN BREAST-CANCER AND SUPPRESSION OF THE NEOPLASTIC PHENOTYPE USING WILD-TYPE P53
    RUNNEBAUM, IB
    KIEBACK, DG
    FRIEDMANN, T
    SUKUMAR, S
    KREIENBERG, R
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 834 - 836
  • [33] ALTERED EXPRESSION OF WILD-TYPE P53 TUMOR SUPPRESSOR GENE DURING MURINE EPITHELIAL-CELL TRANSFORMATION
    HAN, KA
    KULESZMARTIN, MF
    CANCER RESEARCH, 1992, 52 (03) : 749 - 753
  • [34] A new strategy to resume the apoptosis activity of p53 in leukemia cell lines retaining wild-type p53
    Liu, Ze-Jun
    Xin, Hai-Ming
    Chen, Jie
    Lu, Xin
    Zhong, Shan
    Gu, Shou-Zhi
    Wang, Gang
    Liu, Li
    Cai, Yun
    Hou, Lu
    LEUKEMIA RESEARCH, 2007, 31 (08) : 1156 - 1158
  • [35] The tumor suppressor p53 - Cancer and aging
    Feng, Zhaohui
    Hu, Wenwei
    Rajagopal, Gunaretnam
    Levine, Arnold J.
    CELL CYCLE, 2008, 7 (07) : 842 - 847
  • [36] Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol
    Mukhopadhyay, T
    Roth, JA
    ONCOGENE, 1997, 14 (03) : 379 - 384
  • [37] Role of p53 in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53
    Ji, Wansheng
    Ma, Jingrong
    Zhang, Hongmei
    Zhong, Hua
    Li, Lei
    Ding, Na
    Jiao, Jianxin
    Gao, Zhixing
    MOLECULAR MEDICINE REPORTS, 2015, 12 (01) : 691 - 695
  • [38] Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol
    Tapas Mukhopadhyay
    Jack A Roth
    Oncogene, 1997, 14 : 379 - 384
  • [39] p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
    Jean-Christophe Bourdon
    Marie P Khoury
    Alexandra Diot
    Lee Baker
    Kenneth Fernandes
    Mustapha Aoubala
    Philip Quinlan
    Colin A Purdie
    Lee B Jordan
    Anne-Catherine Prats
    David P Lane
    Alastair M Thompson
    Breast Cancer Research, 13
  • [40] p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
    Bourdon, Jean-Christophe
    Khoury, Marie P.
    Diot, Alexandra
    Baker, Lee
    Fernandes, Kenneth
    Aoubala, Mustapha
    Quinlan, Philip
    Purdie, Colin A.
    Jordan, Lee B.
    Prats, Anne-Catherine
    Lane, David P.
    Thompson, Alastair M.
    BREAST CANCER RESEARCH, 2011, 13 (01):